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A B S T R A C T
Methodology to detect and study de novo human T-cell leukemia virus (HTLV)-1 infection is required to further
our knowledge of the viruses’ mechanisms of infection and to study potential therapeutic interventions. Whilst
methodology currently exists, utilisation of an anti-Tax antibody to detect de novo Tax expression in permissive
cells labelled with cell tracker allowing for the detection by flow cytometry of new infection after co-culture with
donor cell lines productively infected with HTLV-1 is an alternative strategy. Using this methodology, we have
been able to detect de novo infection of the T cell line HUT78 following co-culture with the productively infected
HTLV-1 donor cell line MT-2 and to confirm that infection can be effectively blocked with well characterised
infection inhibitors. This methodology will benefit experimental studies examining HTLV infection in vitro and
may aid identification of therapeutic agents that block this process.
1. Introduction
Worldwide an estimated 10–15 million people live with HTLV-1
(Gessain and Cassar, 2012), with areas of high endemicity in Japan,
West Africa, South America, Caribbean islands, Romania, Iran, Middle
East and Australo-Melanesia, where the prevalence ranges from 3 to
50% (Einsiedel et al., 2016; Gessain and Cassar, 2012; Murphy, 2016).
There is currently no cure for HTLV-1 infection or its associated dis-
eases and it has been considered a neglected virus. HTLV-1 is a milk-
and blood-borne and sexually transmitted virus causing significant
mortality and morbidity in patients who develop disease such as HTLV
associated myelopathy/Tropical Spastic Paraparesis (HAM/TSP) and
adult T-cell leukemia/lymphoma (ATL), making HTLV-1 a significant
threat to public health. Translational research is required to identify
pre- and post-exposure interventions similar to HIV-1 infection.
In vitro HTLV-1 infection studies and syncytium-assays are used to
further our understanding of the mechanisms of HTLV-1 infection and
to investigate novel drug inhibitors. In vitro cell-free HTLV-1 infection
has been reported (Fan et al., 1992; Jones et al., 2008), but is an in-
efficient process. Therefore co-cultures of productively infected HTLV-1
donor cells with permissive cells are commonly used to study in vitro de
novo infection (Feuer and Green, 2005). Typically, new infection is
detected through polymerase chain reaction of HTLV-1 specific Tax
DNA after 24 h of co-culturing permissive cells with irradiated donor
cells followed by several cycles of media changes (Balestrieri et al.,
2008). However, we monitored MT-2 cell viability after 30 Gy of X-ray
irradiation and discovered low numbers of viable cells persist in cul-
ture. Therefore, we observe several potential problems with the cur-
rently established and widely utilised methodology: irradiation and
media changes may not fully remove donor DNA and thus potentially
deliver false positive results in future experiments. Also, since sufficient
time is required to detect Tax DNA, the study of HTLV-1 cell-to-cell
transmission at an early stage remains problematic and, for efficient
discovery of pre- and post-exposure prophylaxis interventions, a good
understanding of early HTLV-1 infection stage is needed.
Recently, novel methodology utilising reporter systems transfected
into permissive cells to drive luciferase expression following HTLV-1
infection has been reported (Gross and Thoma-Kress, 2017). Here, we
describe the novel use of labelling and flow cytometry gating strategies
to determine early infection stage of in vitro de novo HTLV-1 infection,
without the need to irradiate or eliminate donor cells. Flow cytometry is
a powerful tool with a wide variety of applications that fundamentally
interrogates single particles “flowing” through a detector system
(Jahan-Tigh et al., 2012). Flow cytometry allows simultaneous multi-
parametric measurements of physical and chemical characteristics of
thousands of particles per second. Particles tested are commonly cells,
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which can be labelled with fluorescent dyes or cell specific fluorescent
antibodies and we have utilised both these strategies to delineate per-
missive- from donor-cells to detect HTLV-1 specific proteins indicative
of early stage de novo infection. In addition, this methodology could be
used to identify novel cell-to-cell transmission targets through HTLV-1
infection inhibitors, in more physiological systems such as organo-ty-
pical explant models to advance the identification of specific HTLV-1
cell entry inhibitors.
2. Methods
2.1. Cells and co-cultures
HUT78 cells were from the NIBSC, Potters Bar, UK, donated by Dr A
Doyle, ECACC (Gazdar et al., 1980); MT-2 cells (Miyoshi et al., 1981)
were a gift from Graham Taylor, Imperial College, London. Both cell
lines were routinely cultured under standard tissue culture conditions,
37 °C with 5% CO2 in air, in Roswell Park Memorial Institute 1640
(RPMI) containing 10% FBS, 2mM L-glutamine, 10mM HEPES, 100 U/
ml penicillin and 100 μg/ml streptomycin (all from Invitrogen, Paisley,
UK).
Prior to co-culture establishment, HUT78 cells were harvested and
resuspended at 1× 106 cells/ml in pre-warmed serum-free RPMI media
containing CellTracker Orange CMRA dye (Invitrogen) used 1:5000 for
15min at 37 °C. Cells were centrifuged and resuspended at 1× 106 in
serum-free RPMI alone for 30min at 37 °C. Cells were then centrifuged
again and resuspended at 0.8× 106 cells/ml for co-culture. Co-cultures
were established between the HUT78 and MT-2 cell lines at a 1:1 ratio
for 24 h at a seeding density of 0.8× 106 cells/ml; mono-cultures of
cells treated in the same way were established at the same cell density
to serve as controls. Co-cultures were also established in the presence of
10 μM cytochalasin B (Fisher Scientific, Loughborough, UK) or 0.5mM
sodium valproate (Santa Cruz Biotechnology, Heidelberg, Germany).
2.2. Antibodies, labelling and flow cytometry
Following co-culture, cells were collected and fixed in 2% ultrapure
methanol free paraformaldehyde (Park Scientific, Northampton, UK) in
PBS for 10min at room temperature, washed and resuspended in per-
meabilisation buffer: PBS+ 7% normal goat serum+0.2% saponin
(Goon et al., 2002) for 10min. Cells were stained using an optimised
concentration of anti-Tax antibody (clone: Lt-4; kindly provided by
Tanaka Y, Ryukyu University (Lee et al., 1989)), or equivalent con-
centration of IgG3 isotype control (eBioscience, Altrincham, UK), in
permeabilisation buffer for 20min. Following two washes in permea-
bilisation buffer, cells were incubated in permeabilisation buffer con-
taining goat anti-mouse IgG3:SureLight APC conjugated secondary an-
tibody (Cambridge Bioscience, Cambridge, UK) for 20min. Two further
washes with permeabilisation buffer followed by two washes with PBS
were performed prior to analysis on a FACSArray flow cytometer (BD
Biosciences, Oxford, UK). In the co-cultures, a gating strategy was de-
vised that selected for cells positive for CellTracker Orange in the FSC/
SSC region of HUT78 cells. A region gate was established using the
isotype controls such that the percentage of cells staining positive with
the anti-Tax antibody could be calculated. To examine MT-2 cells and
for the monoculture MT-2 control, a gating strategy was established for
the cells based upon MT-2 FSC/SSC and events negative for CellTracker
Orange.
2.3. Control: Tax quantification by real time polymerase chain reaction
DNA was extracted from cell lines using the QIAamp DNA mini kit
(Qiagen, Manchester, UK) before being serially diluted to establish
standard curves consisting of 20,000 to 2 β-globin copies and 70,000 to
7 HTLV-1 Tax copies, as previously described (Demontis et al., 2013).
Real time polymerase chain reaction (PCR) was performed using fast
SYBR green mastermix (Applied Biosystems, Loughborough, UK) and
2.5 μM or 5 μM of each forward (F) and reverse (R) primer for Tax (F:
5′-CGGATACCCAGTCTACGTGT-3′, R: 5′-GAGCCGATAACGCGTCCA
TCG-3′) or β-globin (F: 5′-GCAAGGTGAACGTGGATG-3′, R: 5′-TAAGG
GTGGAAAATTGACC-3′), respectively. PCR was performed on an Ap-
plied Biosystems Prism 7300; thermal cycler conditions were: 95 °C for
20 s, followed by 40 amplification cycles of 95 °C for 15 s and 60 °C for
60 s. Tax DNA copy number was calculated from the standard curves
normalized to the number of β-globin copies.
3. Results
3.1. Incomplete removal of HTLV-1 donor cells by irradiation
MT-2 cell viability was monitored daily after a relevant irradiation
dose (30 Gy); small numbers of cells, on average 0.12× 106 cells/ml,
persisted to 240 h (Supplementary Fig. 1). A higher irradiation dose,
200 Gy, was tested but a small proportion of the cells again remained
viable, on average 0.07×106 cells/ml (Supplementary Fig. 1). These
experiments were replicated by other researchers with similar results
(Personal communication, David Brighty, University of Dundee). A
second productively infected HTLV-1 cell line, HUT102, was compared
and, similarly, a small percentage also survived to 240 h after 30 Gy
irradiation (data not shown).
3.2. Optimisation of our in vitro de novo cell-to-cell infection system
HUT78 cells were selected as our permissive cells; amongst avail-
able T cell lines (HUT78, CEM and Jurkat) they expressed greatest
neuropilin and GLUT-1 (Supplementary table 1), cell surface mediators
of HTLV-1 entry. MT-2 cells were selected as our HTLV-1 donors since
they express 1.68 times more Tax by qRTPCR than HUT102 and express
markedly higher levels of Tax, p19 and gp46 by flow cytometry
(Supplementary Table 2).
3.3. Establishment of a flow cytometry system capable of detecting de novo
HTLV-1 infection in permissive cells after co-culture
HUT78 cells are discernible from MT-2 cells based upon forward
and side scatter properties (Supplementary Fig. 2) but we loaded
HUT78 cells with a fluorescent cell tracker dye prior to the co-culture
experiments to allow more robust flow cytometric delineation.
Typically,> 95% of HUT78 cells become stained and are strongly,
fixation resistant, fluorescent after dye incubation, making them un-
mistakable from MT-2 cells (Supplementary Fig. 2). As per manu-
facturer declarations, HUT78 cells were unable to transfer dye to other
cells in co-culture when monitored for up to three days (data not
shown).
Productively HTLV-1 infected MT-2 cells express high levels of
HTLV-1 specific p19, gp46 and Tax; HTLV-1 naïve HUT78 cells are
negative for Tax by intracellular flow cytometry (Fig. 1) and im-
munofluorescence (Supplementary Fig. 3) and lack p19 and gp46 ex-
pression (data not shown). Initially, the cell-surface markers p19 and
gp46 were trialled as markers of de novo HTLV-1 infection of HUT78
cells after co-culture with HTLV-1 donor MT-2 cells and indeed HUT78
appeared to stain positively for these markers after a 24 -h co-culture
(data not shown). However, the addition of the protein synthesis in-
hibitor cycloheximide into the co-culture system did not completely
abolish detection of p19 and gp46 expression on co-cultured HUT78,
which could not sufficiently rule out potential membrane transfer be-
tween MT-2 and HUT78 cells as the source of p19 or gp46 on the
HUT78 cells. We therefore chose the expression of intracellular Tax as
the marker for de novo infection of naive HUT78 cells with HTLV-1,
which cannot be attributed to membrane transfer.
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3.4. Flow cytometric gating strategy
The ability to discern HUT78 cells from MT-2 donor cells forms a
critical part of our flow cytometry gating strategy. Cellular debris,
commonly observed in long-term cell cultures, are first excluded by
forward / side scatter segregation. The cells of interest are enriched by a
size exclusion gate, after which any none-fluorescent cells, i.e. MT-2
cells, or HUT78 cells that had not taken up cell-tracker stain, are then
excluded from future analyses using a conservative segregatory gating
strategy on only strongly fluorescent cells (Supplementary Fig. 2).
3.5. Analysis of HTLV-1 infection in HUT78 by MT-2 cells at 24 h post co-
culture and infection inhibition studies
When HUT78 cells were co-cultured 1:1 with MT-2 cells, a popu-
lation of approximately 2.3% expressed Tax (Fig. 2) as visualised
through flow cytometry. Hence, de novo HTLV-1 infection of HUT78
was detectable in this system at an early time point of only 24 h.
The HTLV-1 infection inhibitors cytochalasin B (Manel et al., 2003)
or sodium valproate (Afonso et al., 2010) were utilised to validate our
demonstration of de novo infection. We conducted two inhibition stu-
dies, firstly the addition of cytochalasin B, which has been shown to
inhibit HTLV-1 infection via GLUT-1 receptor interaction, rather than
impacting actin microfilaments, (Manel et al., 2003), into the co-culture
reduced the percentage of Tax positive HUT78 cells, i.e. reduced HTLV-
1 de novo infection, by 55.9%. However, cytochalasin B appeared to
affect MT-2 cell viability (Supplementary Fig. 4A) and Tax expression
levels (Supplementary Table 3) so a potentially detrimental effect of
cytochalasin B on the infectivity of MT-2 cells reducing their
infectiousness could not be ruled out. Treatment of MT-2 cells with
sodium valproate, which inhibits histone deacetylation, had no effects
on their viability (Supplementary Fig. 4A) nor Tax expression (Sup-
plementary Table 3 & Supplementary Fig. 4B). In our second inhibition
study, including sodium valproate in the co-culture reduced the re-
sulting percentage of Tax expressing HUT78 cells, i.e. reduced HTLV-1
infection of HUT78 cells, by 23.5% (Fig. 3).
4. Discussion
We sought alternative methodology to examine early de novo in vitro
HTLV-1 infection; the rationale being that the most commonly used
current methodology employs DNA extraction from co-cultures reliant
on irradiation induced donor cell death, and their subsequent removal
over time, not suited for early infection studies. We recognised that
small percentages of donor cells appear resistant to irradiation and
maintain their viability in culture; DNA from irradiation resistant cells
might contaminate DNA extractions from co-culture systems producing
false-positive detections of HTLV-1 DNA by qPCR. We hereby present
methodology to measure earlier ‘true’ de novo in vitro HTLV-1 infections
via flow cytometric detection of induced Tax expression in newly in-
fected cells.
After 24 h co-culture with HTLV-1 donor MT-2 cells> 2% of per-
missive HUT78 cells, a male HTLV-1 negative cell line derived from a
lymphoma patient with Sezary syndrome (Bunn and Foss, 1996),
started to express detectable HTLV-1 specific Tax protein visualised by
the highly specific anti-Tax antibody, clone Lt-4 (Tanaka et al., 1990),
using flow cytometry. We conclude that this is de novo Tax expression in
previously Tax negative cells indicative of DNA integration into the
Fig. 1. MT-2 cells show positive Tax expression whilst HUT78 cells are negative. Representative histograms of three separate experiments performed in
triplicate showing averaged data of at least 5000 acquired cells of MT-2 cells (A, C) or HUT78 cells (B, D) stained with isotype control (A, B) or anti-Tax antibody (C,
D).
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HUT78 genome and hence de novo HTLV-1 infection. We recognise the
possibility of exosomal or syncytial transfer of Tax (Sun et al., 2006) as
a small but potential caveat to our methodology. Detection of Tax ex-
pression was selected over that of p19 or gp46 due to potential meth-
odological issues of membrane-transfer during co-culture and it would
be interesting to examine de novo expression of any of these markers,
and thus de novo infection, in cell-free infection studies that these
methodological caveats would not affect. In our opinion this metho-
dology is not limited to examining infection only of HUT78 cells by
MT2 cells. This methodology would be transferable to study infection
between cell types available to other researchers. MT2 and HUT78 were
selected here only to establish this methodology, based upon a hy-
pothesis that they were the most infective, based on higher expression
of Tax than HUT102′s, and permissive, due to higher expression of
neuropilin and GLUT-1 than CEM and Jurkat’s of the lines available to
us.
An important methodological note is that several secondary anti-
bodies were trialled and all but a highly specific, cross absorbed, anti-
IgG3 secondary antibody recognised Lt-4 non-specifically (data not
shown) (Goon et al., 2002). Similarly the anti-IgG3 antibody was
carefully titrated since usage above 1:500 (0.2 μg/ml) produced non-
specific binding (data not shown); antibody titration is likely to be re-
quired for each cell type and any alternative application used. Our
secondary antibody, being SureLight APC conjugated, defined usage of
the CellTracker orange dye; our methodology is adaptable if
alternatively conjugated secondary antibodies are used with an ap-
propriately segregating CellTracker dye, with several different fluor-
escent emitters available commercially.
Previously, Mosley et al utilised flow cytometry to show Tax ex-
pression in HTLV-1 infected cells but did not look at de novo infection
(Mosley et al., 2006). Lt-4 antibody has been used to demonstrate
HTLV-1 infection of Jurkat cells (Toulza et al., 2010) and cell-free virus
infection of monocyte-derived dendritic cells (Manuel et al., 2009) and
Rikzallah et al reported dendritic cell infection by measuring Lt-4 levels
using flow cytometry (Rizkallah et al., 2017). However, to our knowl-
edge, detection of Tax using Lt-4 has not been previously used to ex-
amine de novo HTLV-1 infection at early time points nor has this
methodology been used to assess the ability of candidate drugs to in-
hibit infection. Our use of Lt-4 as a marker of HTLV-1 infection relies on
efficient segregation of donors cells through flow cytometric gating.
This could be achieved using forward and side scatter properties in flow
cytometric analyses with the different properties of the two cell types in
our system but we chose to use an additional cell identifier, a cell
tracker dye in the permissive cells, to make the identification process
more robust. A conservative gating strategy is notable to avoid detec-
tion of donor cells, with this being operator controllable in our system.
Our de novo infection could be effectively blocked by two known in
vitro HTLV-1 infection inhibitors: cytochalasin B [13] and sodium
valproate [14]. Inhibition levels were consistent with others and we
believe our methodology could identify novel drugs in ligand screening
studies of semi-high-throughput given our assay’s capability of de-
termining early infection / infection-inhibition. Reporter cell systems
have also been developed (Gross and Thoma-Kress, 2017) that offer a
similarly effective alternative approach to qPCR methodologies to study
HTLV-1 infection and have also been proposed to be useful to study
novel infection inhibitors (Abdizadeh et al., 2017). However, we pro-
pose that our methodology has the advantage over reporter cell systems
and therefore could also be utilised to study de novo HTLV-1 infection of
cervical tissue in more physiologically relevant organo-typical models,
reminiscent of the studies employed to study HIV-1 infection (Dezzutti
et al., 2013). Preliminary studies not described here used MT-2 or
C1866 (negative control) cell co-culture with ex vivo primary human
cervical tissue followed by cervical tissue digestion using collagenase II
(Hagman et al., 2012) and a gentleMACs dissociator available from
Miltenyi Bioscience (Messier et al., 2012) to isolate single cells suitable
for flow cytometry. Cervical cells were labelled with antibodies against
p19 and gp46, as described here, and a small percentage of non-donor
cells (CD3+/CD4+, non-MT-2, cervical T cells) were analysed with the
finding that C1866 cells induced no meaningful expression of p19 and
gp46 whilst substantial levels were found on cells from tissue co-cul-
tured with MT-2 cells (data not shown). This was a promising and en-
couraging initial result but significant future optimisation would be
required and expression of Tax should be optimised as the de novo in-
fection marker. Using a methodology which detects early HTLV-1 de
novo infection and its blockade reliably, is necessary for future pre- and
post-exposure prophylaxis as well as microbicide drug testing.
5. Conclusions
Effective experimental techniques are required to detect de novo
HTLV-1 infection in vitro at early time points; we now show that the
detection of de novo HTLV-1 Tax expression in permissive cells is pos-
sible through the use of a highly selective anti-Tax antibody and a
specific secondary antibody coupled with cell-tracker labelling and ef-
fective gating strategies to discriminate between newly infected- and
donor-cells by flow cytometry. We believe this is a technological ad-
vance that provides an alternative to current methodologies, particu-
larly at early time points of infection, and could contribute to increased
understanding of HTLV-1 infection mechanisms and potentially clini-
cally relevant inhibitor investigations.
Fig. 2. HUT78 cells become Tax positive after co-culture with MT-2 in-
dicative of de novo HTLV-1 infection. Representative histogram of three ex-
periments performed in triplicate showing averaged data of at least 5000 ac-
quired cells: events in the P4 gate are HUT78 cells staining positive for Tax (A)
and average quantified data, mean ± S.D. (B).
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